"ARV drugs adverse events, case definition, grading, laboratory diagnosis and treatment monitoring"

A meeting of experts, jointly organized by WHO/HIV and PSM Departments, and the FORUM for HIV Collaborative Research

28-29 February 2008
WHO, Geneva

(D Building, ground floor, Kofi Annan meeting room)

AGENDA
Thursday, 28 February 2008

08.30-09.00 Registration

Plenary Session 1: Meeting Opening
Chair: Dr. H. Hogerzeil, Director HQ/DG/HSS/PSM

09.00-10.00 Welcome address
Dr. K. De Cock, Director HQ/HTM/HIV

- Introduction to the meeting.
- Meeting objectives.
- Key note speech: Definitions of AE related to ARVs: What are we talking about?
  Dr. J. Lundgren

AE related to ARVs: available data from UPSALA
  Dr. M. Lindquist

10.15-10.30 Coffee Break

Plenary Session 2: Definitions of Adverse Events linked to Antiretroviral Drugs
Chair: Dr. P. Munderi
Panel: Presenters

10.30-10.50 Overview of current knowledge on adverse effects of ARVs and existing definitions: needs and gaps:
  Dr. N. Bakare

10:50-11:15 AE related to ARVs: the cohort perspective.
  A clinician's perspective on AEs related to ARVs.
  Dr. J. Hakim

11:15-11:30 Presentation of MedDRA
  Dr. A. Zhao-Wong

11:30-12:15 Introduction to the working group sessions: expected outcomes
  Dr. M. Diepart

- Discussion and getting a consensus on definitions: challenges and limits
  Dr. D. Coulter

12:15-12.30 Groups constitution*
  M. B. Cheng

12.30-13.30 Lunch

Working groups sessions

13.30-16.00 Working group sessions: 5 parallel sessions by thematic areas*
  List of definitions of AE/ARVs
  Setting methodology and criteria for case definition

16.00-16.15 Coffee Break

Plenary session
Chair: Dr. A. Oto Dodoo
Panel: Rapporteurs of working groups

16.15-18.00 Reports by working groups (5 minutes by group)
  Discussion: reaching a consensus on the list of AE/ARVs definitions and a methodology for setting the case definition

18.00-18.40 Reception: Cocktail Building D Ground Floor

19:00 Dinner offered by the Forum for Collaborative Research at "Le Vieux Bois"
  Av. de la Paix, Genève
Friday, 29 February 2008

Plenary session 4:                                                   Chair : Dr S. Eholié
Panel: Chairs of the working groups Day 1

09:00-9:45 Report of first day; discussion: methodology to identify and manage adverse events linked to ARVs

Working group sessions
9:45-10:30 Report of working groups: Work in plenary
10.30-10:45 Coffee Break
10.45-12:30 Plenary work ctd: Review of priority listing of adverse events linked to ARVs.

12:30-13:30 Lunch Break

Plenary  session 5:                                                   Chair: Dr  C. Williams
Panel: Chairs of the working groups Day 2

14:00-15:30 Plenary work ctd: Meeting consensus

15.30-16:00 Coffee Break

Plenary session 6:                                                   Chair Dr H. Nakatani, ADG, HQ/HTM Assistant
Panel: Dr Gilks; Dr J Aberg

16:00-17.30 Next steps Dr. J. Aberg
Dr. C. Gilks

17.30 Close meeting Dr K. De Cock, Director HQ/HTM/HIV
Dr H. Hogerzeil, Director HQ/HSS/QSM

Working groups were constituted with representatives from different fields of expertise, cohorts, clinicians, PV specialists.

First day, 5 groups organized around different thematic areas:
1. Blood and lymphatic system disorders; Cardio vascular; Respiratory; General disorders:
2. Skin and subcutaneous tissue; Immune system disorders; Neoplasms benign, malignant and unspecified:
3. Metabolism and nutrition; Gastrointestinal; Hepatobiliary; Renal and urinary disorders:
4. Musculoskeletal and connective tissue; Nervous system; Psychiatric disorders:
5. Reproductive system; Pregnancy; Puerperium and perinatal; Congenital and genetic disorders: